8 results on '"Crawley, Danielle"'
Search Results
2. Additional file 1: Appendix 1. of Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer
- Author
-
Crawley, Danielle, Chandra, Ashish, Loda, Massimo, Gillett, Cheryl, Cathcart, Paul, Challacombe, Ben, Cook, Gary, Cahill, Declan, Olalla, Aida Santa, Cahill, Fidelma, Gincy George, Rudman, Sarah, and Hemelrijck, Mieke Van
- Abstract
Informed Consent Form. (DOC 213Â kb)
- Published
- 2017
- Full Text
- View/download PDF
3. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
- Author
-
Crawley, Danielle, Garmo, Hans, Rudman, Sarah, Stattin, Pär, Häggström, Christel, Zethelius, Björn, Holmberg, Lars, Adolfsson, Jan, and Van Hemelrijck, Mieke
- Subjects
Male ,Risk ,Antineoplastic Agents, Hormonal ,endocrine system diseases ,androgen deprivation therapy ,Endocrinology and Diabetes ,Biomarkers, Tumor ,Humans ,Registries ,Aged ,Neoplasm Staging ,Proportional Hazards Models ,Aged, 80 and over ,Sweden ,Cancer och onkologi ,Incidence ,Prostatic Neoplasms ,Androgen Antagonists ,Middle Aged ,prostate cancer ,Diabetes Mellitus, Type 2 ,Cancer and Oncology ,Endokrinologi och diabetes ,type two diabetes ,Neoplasm Grading ,Orchiectomy ,Cancer Epidemiology - Abstract
Androgen deprivation therapy (ADT) for prostate cancer (PCa) increases risk of type 2 diabetes (T2DM); however the association between types and duration of ADT has not been fully elucidated. We examined how type and duration of ADT affects risk of T2DM. Using data from Prostate Cancer database Sweden (PCBaSe) we investigated risk of T2DM in a cohort of 34,031 men with PCa on ADT; i.e., anti‐androgens (AA), orchiectomy, or gonadotropin‐releasing hormone (GnRH) agonists compared to an age‐matched, PCa‐free comparison cohort (n = 167,205) using multivariate Cox proportional hazard regression. T2DM was defined as a newly filled prescription for metformin, sulphonylurea, or insulin in the Prescribed Drug Register. A total of 21,874 men with PCa received GnRH agonists, 9,143 AA and 3,014 underwent orchiectomy. Risk of T2DM was increased in men in the GnRH agonists/orchiectomy group during the first 3 years of ADT [i.e., 1 − 1.5 years HR: 1.61 (95%CI: 1.36 − 1.91)], compared to PCa‐free men. The risk decreased thereafter (e.g., 3 − 4 years HR: 1.17 (95% CI: 0.98 − 1.40)). Conversely, no increased risk was seen in men on AA (HR: 0.74 (95%CI: 0.65 − 0.84). The incidence of T2DM per 1,000 person‐years was 10 for PCa‐free men, 8 for men on AA, and 13 for men on GnRH agonists/orchiectomy. Duration of ADT has a significant impact on risk of T2DM. With the peak after three years of treatment, our data indicates that men on ADT, even for a limited period of time, such as adjuvant to radiotherapy, are at increased risk of T2DM., What's new? All treatments involve tradeoffs. For patients with prostate cancer, treatment with androgen deprivation therapy (ADT) can lead to an increased risk of type II diabetes. These authors set out to analyze how the duration of treatment, and the type of ADT, affect diabetes risk. They collected data on patients receiving three types of ADT: anti‐androgens, gonadotropin releasing hormone agonists, and orchiectomy, and compared them with age‐matched, cancer‐free controls. The risk of diabetes peaked after 3 years of treatment with GnRH agonists or orchiectomy. By contrast, patients receiving anti‐androgens showed no increase in diabetes risk relative to cancer‐free controls.
- Published
- 2016
4. Serum glucose and risk of cancer: a meta-analysis
- Author
-
Crawley, Danielle J., Holmberg, Lars, Melvin, Jennifer C., Loda, Massimo, Chowdhury, Simon, Rudman, Sarah M., and Van Hemelrijck, Mieke
- Subjects
Meta-analysis ,Cancer och onkologi ,Cancer Research ,Glucose ,Oncology ,Cancer and Oncology ,Diabetes ,Genetics ,Metabolic syndrome ,Cancer - Abstract
Background: Raised serum glucose has been linked to increased risk of many solid cancers. We performed a meta-analysis to quantify and summarise the evidence for this link. Methods: Pubmed and Embase were reviewed, using search terms representing serum glucose and cancer. Inclusion and exclusion criteria focused on epidemiological studies with clear definitions of serum glucose levels, cancer type, as well as well-described statistical methods with sufficient data available. We used 6.1 mmol/L as the cut-off for high glucose, consistent with the WHO definition of metabolic syndrome. Random effects analyses were performed to estimate the pooled relative risk (RR). Results: Nineteen studies were included in the primary analysis, which showed a pooled RR of 1.32 (95% CI: 1.20 - 1.45). Including only those individuals with fasting glucose measurements did not have a large effect on the pooled RR (1.32 (95% CI: 1.11-1.57). A stratified analysis showed a pooled RR of 1.34 (95% CI: 1.02-1.77) for hormonally driven cancer and 1.21 (95% CI: 1.09-1.36) for cancers thought to be driven by Insulin Growth Factor-1. Conclusion: A positive association between serum glucose and risk of cancer was found. The underlying biological mechanisms remain to be elucidated but our subgroup analyses suggest that the insulin- IGF-1 axis does not fully explain the association. These findings are of public health importance as measures to reduce serum glucose via lifestyle and dietary changes could be implemented in the context of cancer mortality.
- Full Text
- View/download PDF
5. Hormonal patterns in men with prediabetes and diabetes in NHANES III: possible links with prostate cancer
- Author
-
Kerri Beckmann, Danielle Crawley, William G. Nelson, Elizabeth A. Platz, Elizabeth Selvin, Mieke Van Hemelrijck, Sabine Rohrmann, University of Zurich, Beckmann, Kerri, Crawley, Danielle, Nelson, William G, Platz, Elizabeth A, Selvin, Elizabeth, Van Hemelrijck, Mieke, and Rohrmann, Sabine
- Subjects
Male ,Cancer Research ,610 Medicine & health ,insulin growth factor-I (IGF-I) ,Article ,Prediabetic State ,and sex steroids ,estradiol ,Sex Hormone-Binding Globulin ,Diabetes Mellitus ,Humans ,Testosterone ,1306 Cancer Research ,Insulin-Like Growth Factor I ,Prostatic Neoplasms ,10060 Epidemiology, Biostatistics and Prevention Institute (EBPI) ,prostate cancer ,Nutrition Surveys ,insulin growth factor-binding protein 3 (IGFBP-3) ,Cross-Sectional Studies ,Insulin-Like Growth Factor Binding Protein 3 ,Oncology ,diabetes mellitus ,testosterone ,2730 Oncology ,C-peptide - Abstract
Refereed/Peer-reviewed Purpose: Pathways involving sex hormones and insulin-like growth factors (IGFs) have been proposed to explain, in part, the lower risk of prostate cancer among men with diabetes. To gain insights into potential biological mechanisms we explored differences in serum concentrations of sex hormones and IGFs across the trajectory from normoglycemia to prediabetes to poorly controlled diabetes. Methods: Using cross-sectional data from the National Health and Nutrition Examination Survey III we examined differences in levels of circulating sex hormones, sex hormone-binding globulin (SHBG), IGF-1, and IFG-binding protein 3 (IGFBP-3), according to diabetes status: no diabetes [n = 648], prediabetes [n = 578], undiagnosed diabetes [n = 106], well-controlled diabetes [n = 42], and poorly controlled diabetes [n = 56]. Adjusted geometric mean concentrations were derived using multivariable linear regression, adjusted for age, race, and other lifestyle factors. Results: Total testosterone concentrations were lower among prediabetics (4.89 ng/mL, 95% confidence interval (CI) 4.95–5.21) than men without prediabetes/diabetes (5.29 ng/mL, 95% CI 5.06–5.53) but did not reduce further across diabetes groups. Concentrations of estradiol, estimated free testosterone, SHGB, IGF-1, and IGFBP-3 did not differ. While the ratio of IGF-1 to IGFBP-3 was lower among men with prediabetics and undiagnosed diabetes than men without prediabetes/diabetes, there was no trend across groups. A positive trend for the ratio of estradiol-to-testosterone levels was observed across groups (p trend = 0.045). Conclusion: Our findings do not provide clear support for either an androgen driven or IGF-driven pathway for the inverse association between diabetes and prostate cancer risk.
- Published
- 2022
6. Metabolic syndrome biomarkers and prostate cancer risk in the UK Biobank
- Author
-
Maria J. Monroy‐Iglesias, Beth Russell, Danielle Crawley, Naomi E. Allen, Ruth C. Travis, Aurora Perez‐Cornago, Mieke Van Hemelrijck, Kerri Beckmann, Monroy-Iglesias, Maria J, Russell, Beth, Crawley, Danielle, Allen, Naomi E, Travis, Ruth C, Perez-Cornago, Aurora, Van Hemelrijck, Mieke, and Beckmann, Kerri
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,Inverse Association ,medicine.medical_specialty ,Waist ,Blood Pressure ,metabolic syndrome ,Cohort Studies ,03 medical and health sciences ,Prostate cancer ,chemistry.chemical_compound ,0302 clinical medicine ,Risk Factors ,Surveys and Questionnaires ,Internal medicine ,medicine ,Humans ,Testosterone ,mediation analysis ,Triglycerides ,Aged ,Biological Specimen Banks ,Proportional Hazards Models ,Glycated Hemoglobin ,Metabolic Syndrome ,business.industry ,Cholesterol, HDL ,Hazard ratio ,Prostatic Neoplasms ,Middle Aged ,medicine.disease ,prostate cancer ,United Kingdom ,Confidence interval ,C-Reactive Protein ,chemistry ,030220 oncology & carcinogenesis ,Cohort ,Glycated hemoglobin ,Waist Circumference ,Metabolic syndrome ,business ,Biomarkers ,glycated hemoglobin - Abstract
We investigated the association between metabolic syndrome (MetS) and its components and risk of prostate cancer (PCa) in a cohort of men enrolled in the UK Biobank. Our study cohort included 220 622 PCa‐free men with baseline measurements of triglycerides (TG), HDL‐cholesterol (HDL), glycated haemoglobin (HbA1c), blood pressure (BP), and waist circumference (WC). Multivariable Cox proportional hazards regression was used to analyse associations with PCa for: individual metabolic components (TG, HDL, HbA1c, BP, WC), combinations of two and three components, and MetS overall (three or more components). We conducted mediation analyses to examine potential hormonal and inflammatory pathways (total testosterone (TT), C‐reactive protein (CRP), insulin‐like growth factor 1 (IGF‐1)) through which MetS components may influence PCa risk. A total of 5409 men in the study developed PCa during a median follow‐up of 6.9 years. We found no significant association between MetS and PCa risk (Hazard Ratio (HR): 0.99, 95% Confidence Interval (CI): 0.92‐1.06). No associations were found with PCa risk and individual measurements of TG, HDL, BP or WC. However, an inverse association was observed with elevated HbA1c (≥42 mmol/mol) (HR: 0.89, 95%CI: 0.79‐0.98). Consistent inverse associations were observed between HbA1c and risk of PCa. Mediation analysis revealed TT, CRP and IGF‐1 as potential mediating factors for this association contributing 10.2%, 7.1% and 7.9% to the total effect, respectively. Overall MetS had no association with PCa risk. However, a consistent inverse association with PCa risk was found for HbA1c. This association may be explained in part through hormonal and inflammatory pathways.
- Published
- 2021
7. Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe : A Nationwide Case-Control Study
- Author
-
Jonathan Parker, Danielle Crawley, Hans Garmo, Bertil Lindahl, Johan Styrke, Jan Adolfsson, Mats Lambe, Pär Stattin, Mieke Van Hemelrijck, Kerri Beckmann, Parker, Jonathan, Crawley, Danielle, Garmo, Hans, Lindahl, Bertil, Styrke, Johan, Adolfsson, Jan, Lambe, Mats, Stattin, Pär, Van Hemelrijck, Mieke, and Beckmann, Kerri
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,case-control study ,Population ,direct anticoagulant agents ,lcsh:RC254-282 ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Internal medicine ,Medicine ,education ,Original Research ,education.field_of_study ,Cancer och onkologi ,detection bias ,business.industry ,Warfarin ,Case-control study ,Odds ratio ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,prostate cancer ,Confidence interval ,warfarin ,Prostate-specific antigen ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cancer and Oncology ,Population study ,business ,medicine.drug - Abstract
Refereed/Peer-reviewed Existing literature examining warfarin's association with prostate cancer (PCa) risk provides conflicting results, while the association with direct oral anticoagulants (DOACs) has not yet been studied. We investigated the association of warfarin and DOAC use on PCa risk among men within the population-based Prostate Cancer database Sweden (PCBaSe), using a case-control design. The study population included PCa cases diagnosed 2014–2016 and five age-matched PCa-free controls. Conditional logistic regression was used to estimate odds ratios (ORs) with 95% confidence intervals (CI) for PCa associated with warfarin and DOAC use, adjusted for marital status, education level, other drug use, and comorbidities. Among 31,591 cases and 156,802 controls, there were 18,522 (9.8%) warfarin and 4,455 (2.4%) DOAC users. Warfarin ever-use was associated with reduced risk of PCa overall (OR 0.92 95% CI 0.88–0.96) as were both past and current use. DOAC use was not associated with PCa risk. For some warfarin exposures, decreased risk was observed for unfavorable PCa (high risk/locally advanced/distant metastatic) but not with favorable PCa (low/intermediate risk). Increased risk of favorable PCa was observed for men whose initial warfarin exposure occurred in the 12 month period before diagnosis (OR 1.39; 95% CI 1.13–1.70). Our findings are consistent with previous publications reporting decreased PCa risk with warfarin exposure. Increased risk of favorable PCa suggests detection bias due to increased prostate specific antigen testing when starting on warfarin. Decreased overall PCa risk could reflect bias due to reduced biopsy rates among long-term warfarin users.
- Published
- 2020
8. Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results
- Author
-
Anna Lantz, Hans Garmo, Danielle Crawley, Tobias Nordström, Markus Aly, Martin Eklund, Henrik Olsson, Kerri Beckmann, Noor Binti Abd Jalal, Mieke Van Hemelrijck, Jan Adolfsson, Beckmann, Kerri, Crawley, Danielle, Nordström, Tobias, Aly, Markus, Olsson, Henrik, Lantz, Anna, Binti Abd Jalal, Noor, Garmo, Hans, Adolfsson, Jan, Eklund, Martin, and Van Hemelrijck, Mieke
- Subjects
Adult ,Male ,medicine.medical_specialty ,Prostate biopsy ,Biopsy ,Population ,Lower risk ,Rate ratio ,Cohort Studies ,Prostate cancer ,Prostate ,Internal medicine ,cancer-risk ,Diabetes Mellitus ,medicine ,Humans ,Hypoglycemic Agents ,Insulin ,Genetic Predisposition to Disease ,Registries ,education ,Aged ,Sweden ,education.field_of_study ,Marital Status ,medicine.diagnostic_test ,business.industry ,Prostatic Neoplasms ,General Medicine ,Odds ratio ,Middle Aged ,Prostate-Specific Antigen ,medicine.disease ,Metformin ,Prostate-specific antigen ,Sulfonylurea Compounds ,medicine.anatomical_structure ,Case-Control Studies ,Educational Status ,business ,antidiabetic medication ,diabetes-mellitus - Abstract
Importance: Diabetic men appear to have a lower risk of prostate cancer. Whether antidiabetic medications are protective or potentially mask prostate cancer by lowering prostate-specific antigen (PSA) levels is unclear. Objective: To examine the associations of antidiabetic medication use with (1) PSA levels, (2) frequency of PSA testing, (3) receipt of biopsy following elevated PSA results, and (4) prostate cancer detection at biopsy. Design, Setting, and Participants: Population-based cohort study using data from the Stockholm PSA and Biopsy Register. Participants were all prostate cancer-free men aged 40 to 79 years residing in Stockholm County, Sweden, between January 1, 2006, and December 31, 2015. Data were analyzed from November 2018 to March 2019. Exposures: One or more prescription for metformin, sulfonylurea, or insulin, as recorded in Sweden's National Prescribed Drug Register. Main Outcomes and Measures: Levels of PSA following first exposure to antidiabetic medications were assessed using multivariable linear regression. Frequency of PSA testing was assessed via multivariable Poisson regression. Biopsy following elevated PSA (≥3.0 ng/mL) and prostate cancer detection at biopsy were assessed via multivariable logistic regression. Results: The cohort of 564 666 men (median [range] age, 65 [40-79] years) consisted of 4583 men initially exposed to metformin, 1104 exposed to sulfonylurea, and 978 exposed to insulin who were age matched with unexposed men (1:5). Exposed men had lower median (interquartile range) PSA levels before starting antidiabetic medications compared with unexposed men (1.2 [0.7-2.5] vs 1.6 [0.8-3.2] ng/mL). After accounting for baseline differences, PSA levels did not vary from those of unexposed men following exposure to antidiabetic medications. Frequency of PSA testing was higher for those receiving metformin (rate ratio, 1.07; 95% CI, 1.06-1.09) and sulfonylurea (rate ratio, 1.06; 95% CI, 1.03-1.08) but was lower for those receiving insulin (rate ratio, 0.79; 95% CI, 0.77- 0.81). Likelihood of biopsy after elevated PSA was lower among men receiving metformin (odds ratio, 0.87; 95% CI, 0.80-0.96) and insulin (odds ratio, 0.83; 95% CI, 0.74-0.93). There were no differences in prostate cancer detection at biopsy, regardless of PSA levels that triggered the biopsy. Conclusions and Relevance: This study's findings do not support the hypothesis that the inverse association between diabetes and prostate cancer is mediated through antidiabetic medications lowering PSA levels to mask prostate cancer. They do suggest potential detection bias due to fewer biopsies among men receiving antidiabetic medications, which may explain the lower prostate cancer risk in men with diabetes. Refereed/Peer-reviewed
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.